Table 1. Demographic Comparison of Patients Who Did or Did Not Receive Monoclonal Antibody Treatment for COVID-19.
| Characteristic | No. (%) | P value | |
|---|---|---|---|
| mAb recipients (n = 201) | Nonrecipients (n = 280) | ||
| Native American ethnicity | 201 (100) | 280 (100) | NA |
| Sex | |||
| Female | 123 (61.2) | 151 (53.9) | .11 |
| Male | 78 (38.8) | 129 (46.1) | |
| Age | |||
| Mean (SD), y | 50 (19) | 43 (19) | <.001 |
| ≥65 y | 53 (26.4) | 45 (16.1) | .006 |
| BMI | |||
| No. of patients | 195 | 274 | |
| Median (IQR) | 35.8 (30.0-40.0) | 35.0 (29.2-38.4) | .15 |
| ≥35a | 118 (60.5) | 163 (59.5) | .82 |
| Comorbiditiesb | |||
| Chronic kidney disease | 14 (7.0) | 14 (5.0) | .36 |
| Diabetes | 85 (42.3) | 112 (43.57) | .78 |
| Immunosuppressive disease | 2 (1.0) | 1 (0.4) | .38 |
| Immunosuppressive treatment | 6 (3.0) | 5 (1.8) | .39 |
| Chronic respiratory disease | 39 (19.4) | 42 (16.8) | .46 |
| Aged ≥55 y with the following: | |||
| Hypertension | 62 (30.9) | 62 (22.1) | .03 |
| Cardiovascular disease | 18 (9.0) | 18 (6.4) | .30 |
| Otherc | 1 (0.5) | 9 (3.2) | .05 |
| Risk factors for severe COVID-19, No.b | |||
| Median (IQR) | 2 (1-3) | 1 (1-2) | .007 |
| ≥1 | 200 (99.5) | 280 (100) | .24 |
| ≥2 | 114 (56.7) | 125 (44.6) | .009 |
| Treatment | |||
| Bamlanivimab | 180 (89.6) | NA | NA |
| Combination of casirivimab and imdevimab | 21 (10.4) | NA | NA |
| Test collection to treatment, median (IQR), h | 23 (3-45) | NA | NA |
| Symptom onset to treatment, median (IQR), dd | 2 (1-3) | NA | NA |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); IQR, interquartile range; mAb, monoclonal antibody; NA, not applicable.
For patients aged 12 to 17 years, BMI in the 85th percentile or higher.
Risk factors based on emergency use authorization criteria were as follows: age 65 years or older, BMI (for patients aged 12-17 years, BMI in the 35th percentile or higher or in the 85th percentile or higher), chronic kidney disease, diabetes, immunosuppressive disease, immunosuppressive treatment, chronic lung disease, and age 55 years or older with hypertension or cardiovascular disease.
Other conditions included end-stage liver disease, congestive heart failure (age younger than 55 years), spina bifida, Down syndrome, or malignant neoplasm.
Among 149 patients with a known symptom onset date; 45 patients (22.4%) were asymptomatic at the time of treatment.